Revista Gastroenterología

April 2022



Updated efficacy and safety data of atezolizumab plus bevacizumab versus sorafenib in unresectable hepatocellular carcinoma:

Even after an additional 12-months follow-up of the IMbrave150 study, atezolizumab plus bevacizumab maintained clinically meaningful survival benefits over sorafenib. After a median 15.6 (range, 0–28.6) months of follow-up, the median overall survival was 19.2 months (95% confidence interval : 17.0–23.7) with atezolizumab plus bevacizumab and 13.4 months (95% CI: 11.4–16.9) with sorafenib (hazard ratio = 0.66; 95% CI: 0.52–0.85; descriptive p < 0.001).

International Autoimmune Hepatitis Group proposes criteria for response to therapy in autoimmune hepatitis:

A consensus process initiated by the International Autoimmune Hepatitis Group (IAIHG) proposes the following criteria: Complete biochemical response: normalization of serum transaminases and immunoglobulin G (IgG) below the upper limit of normal at 6 months after initiation of treatment.Insufficient response by 6 months: failure to meet the above definition.Non-response: < 50% decrease of serum transaminases within 4 weeks after initiation of treatment.Remission: liver histology with a Hepatitis Activity Index < 4/18.Intolerance to treatment: any adverse event possibly related to treatment leading to potential drug discontinuation.

Oesophagus Stomach Duodenum




Login to your account below

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.

Estimado Médico
Para tener acceso a artículos exclusivos de la revista gastroenterología

En su suscripción recibirá mensualmente nuestro boletín con noticias, eventos y sesiones en vivo.

Si ya esta registrado ingrese aquí